Everything below concerns actin binding. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.
Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H68N10O14 | Acetylated heptapeptide form |
| Monoisotopic mass | 888.5 Da | Average mass about 889 Da |
| Appearance | White to off-white solid | Usually supplied as lyophilised powder |
| Solubility class | Highly water soluble | Also dissolves in aqueous buffers |
| Common synonyms | Tbeta4 fragment, thymosin beta-4 (17-23) | Refer to the same sequence |
Material sold under this label typically arrives as a freeze-dried powder in a sealed vial with a certificate of analysis. Such certificates usually report reversed-phase chromatography purity plus a mass confirmation, and stated purities commonly sit between 95 and 99 percent. Counter-ion identity, residual trifluoroacetate, water content, and peptide net weight are separate specifications that a certificate may or may not include. A purity figure alone does not establish sequence identity, so independent mass verification remains the practical check.
The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.
The fragment most often associated with the name carries the sequence Ac-LKKTETQ, matching residues 17 through 23 of thymosin beta-4. That region holds the actin-binding motif responsible for much of the parent protein's biochemical activity. Apart from N-terminal acetylation the peptide is unmodified and contains no disulfide bonds, so it shows little ordered secondary structure in solution. Full-length thymosin beta-4 is instead a 43-residue polypeptide of roughly 4.9 kDa found widely across mammalian cell types.
Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
absolute zero A theoretical condition concerning a system at the lowest limit of the thermodynamic temperature scale, or zero kelvins, at which the system does not emit or absorb energy (i.e. all atoms are at rest). By extrapolating the ideal gas law, the internationally agreed-upon value for absolute zero has been determined as −273.15 °C (−459.67 °F; 0.00 K).
Lately First UK Offshore Wind Champion and Chair, Offshore Wind Acceleration Taskforce. For services to Offshore Wind Energy. Ruth Beatrice Pitter. Member, Anchor Society and Member, Stand Against Racism and Inequality. For services to Equality, to Charity and to the community in Bristol. Andrew Geoffrey Pollock. Founder, CLEVR Money. For services to Financial Inclusion. Phillip George Potter. Regional Lead, West Midlands, Wales and South West, UK Export Finance. For services to Business and to the community in Worcestershire. Jeffrey Richard Powell. Sports Writer and Columnist, Daily Mail. For services to Journalism and to Sport. Patricia Mary Pritchard. For services to Childcare and Early Years. Dr. Heidi Probst. Researcher, Lecturer and lately Director, Health Research Institute, Sheffield Hallam University. For services to Radiography. Howard John Provis. For services to the Welsh Blood Transfusion Service and to the community in Barry and the Vale of Glamorgan. Brian Thomas James Purcell. Lately Northern District Manager, St John Ambulance. For voluntary service in Northern Ireland. Anthony Martin Quinn. Lately Business Development Director, Co-operation Ireland. For services to Community Relations in Northern Ireland. Jayshree Rajkotia. Trustee and Vice Chair, Bharatiya Vidhya Bhavan, Institute of Indian Art and Culture. For services to Indian Culture. Melinda Elizabeth Raker, DL. Founder and Patron, The YANA Charity. For services to Rural Mental Health and Wellbeing. Laura-Jane Rawlings. Chief Executive Officer, Youth Employment UK. For services to Young People.
==== Mass Spectrometry-based Proteomic Methods ==== Conventional shotgun proteomics identification of low abundance proteins in samples remains limited despite advances in Mass Spectrometry (MS) technology. While abundant proteins can be easily detected, possible protease substrates of biological significance, such as cytokines, can be easily overlooked due to their low abundance. Most pre-clearing strategies designed to correct this also risk losing low abundant proteins, thus techniques designed specifically to target protease substrates for identification have been developed. These techniques have coalesced into a new field of positional proteomics or terminomics aimed at identifying protein N- or C-terminal modifications of protease substrates. Terminomic approaches including Terminal Amine Isotopic Labeling of Substrates (TAILS) N-Terminomics, Combined FRActional Diagonal Chromatography (COFRADIC), and C-Terminomics add the level of stringency to conventional shotgun proteomics necessary to make them workhorse of degradomics. TAILS, or “N-Terminomics,” was designed and developed by the Overall Lab to overcome the functional limitations of conventional proteomics by enriching both mature N-terminal peptides and newly generated N-terminal peptides of proteins produced by protease activity. Formaldehyde or isobaric tags including Isotope-coded Affinity Tags (ICAT), 4 to 8 plex Isobaric tag for relative and absolute quantification (iTRAQ), or 10plex Tandem mass tags (TMT) block primary amines prior to trypsin digestion of proteome samples.
. The simulation first updates the infected from the susceptible and then the removed category is updated from the infected category for the next time point (t=1). This describes the flow persons between the three categories. During an epidemic the susceptible category is not shifted with this model,
Sources: en.wikipedia.org
Types include astrocytes, oligodendrocytes, microglia, and Schwann cells. Glia limitans A thin layer of astrocytic endfeet beneath the pia mater that forms part of the barrier separating the brain parenchyma from the cerebrospinal fluid. Glial scar A dense accumulation of glial cells, particularly astrocytes, that forms after central nervous system injury. It helps contain damage but can also inhibit axonal regeneration. Glioblastoma A highly aggressive and malignant brain tumor arising from glial cells. It is the most common primary brain cancer in adults and often has a poor prognosis. Glucocorticoid A class of steroid hormones released by the adrenal cortex in response to stress. They influence metabolism and have significant effects on memory and the hippocampus. Glutamate The main excitatory neurotransmitter in the brain. It is essential for learning, memory, and synaptic plasticity, but excessive levels can cause excitotoxicity. Glutamatergic Describes neurons or synapses that use glutamate as a neurotransmitter. These are the majority of excitatory synapses in the brain. Glycine An inhibitory neurotransmitter found primarily in the spinal cord and brainstem. It acts via glycine receptors and contributes to motor control and reflexes. Golgi cell A type of inhibitory interneuron in the cerebellum that regulates input from mossy fibers to granule cells via GABA release. Golgi stain A silver staining method that randomly labels a small subset of neurons in their entirety, allowing detailed study of neuronal morphology.
West Berlin was under the sovereignty of the Western Allies and neither a Western German state nor part of one. However, it was in many ways integrated with West Germany under a special status. A new delimitation of the federal territory has been discussed since the Federal Republic was founded in 1949 and even before. Committees and expert commissions advocated a reduction of the number of states; academics (Werner Rutz, Meinhard Miegel, Adrian Ottnad, etc.) and politicians (Walter Döring, Hans Apel, and others) made proposals – some of them far-reaching – for redrawing boundaries but hardly anything came of these public discussions. Territorial reform is sometimes propagated by the richer states as a means to avoid or reduce fiscal transfers.
Lung fibrosis is a recognized complication of rheumatoid arthritis. It is also a rare but well-recognized consequence of medications used to treat RA such as methotrexate and leflunomide). Caplan's syndrome describes lung nodules in individuals with RA and additional exposure to coal dust. Exudative pleural effusions are also associated with RA.
This led to the discovery of the same substance he had found in eight other patients. He conducted tests and found reactions that gave rise to benzaldehyde and benzoic acid, which led him to conclude that the compound contained a benzene ring. Further testing showed the melting point to be the same as phenylpyruvic acid, which indicated that the substance was in the urine. In 1954, Horst Bickel, Evelyn Hickmans and John Gerrard published a paper that described how they created a diet that was low in phenylalanine and the patient recovered. Bickel, Gerrard, and Hickmans were awarded the John Scott Medal in 1962 for their discovery. PKU was the first disorder to be routinely diagnosed through widespread newborn screening. Robert Guthrie introduced the newborn screening test for PKU in the early 1960s. With the knowledge that PKU could be detected before symptoms were evident, and treatment initiated, screening was quickly adopted around the world. Ireland was the first country to introduce a national screening programme in February 1966, Austria also started screening in 1966 and England in 1968. In 2017, the European Guidelines were published. They were called for by the patient organizations such as the European Society for Phenylketonuria and Allied Disorders Treated as Phenylketonuria. They have received some critical reception.
Stephen G. Weber is a professor of chemistry and clinical translational science at the University of Pittsburgh. He researches analytical separations theory and its application, and has developed "green" techniques for molecular recognition and microextractions. He is particularly interested in the identification of peptides and dipeptides, and their effects on neurochemistry. He has received a number of awards, including the 2016 Dal Nogare Award for "contributions to the fundamental understanding of the chromatographic process".
Sources: en.wikipedia.org
No. TB-500 is a short synthetic peptide matching residues 17 to 23 of thymosin beta-4, while the parent protein contains 43 residues. The fragment lacks the rest of the protein sequence, so the two are related but not identical.
It consists of leucine, lysine, lysine, threonine, glutamic acid, threonine, and glutamine in that order. The N-terminal leucine is usually acetylated in the forms described in catalogues.
Controlled human data is limited, and most published findings come from cell culture or animal work. This makes it difficult to state clinical effects with confidence.
TB-500 is a name used for a short synthetic peptide fragment taken from the actin-binding region of thymosin beta-4. Material sold under this label is usually a lyophilized powder supplied for laboratory research rather than a licensed medicine. The commonly cited sequence is LKKTETQ.